As of 2025-06-30, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (8.10) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.13 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -358.6%.
The range of the Relative Valuation is (6.59) - (9.03) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 22.6x | 18.8x |
| Forward P/E multiples | 16.5x - 26.9x | 21.7x |
| Fair Price | (6.59) - (9.03) | (8.10) |
| Upside | -310.5% - -388.4% | -358.6% |
| Date | P/E |
| 2025-06-27 | -7.83 |
| 2025-06-26 | -8.00 |
| 2025-06-25 | -8.35 |
| 2025-06-24 | -8.43 |
| 2025-06-23 | -8.53 |
| 2025-06-20 | -8.58 |
| 2025-06-18 | -8.68 |
| 2025-06-17 | -8.63 |
| 2025-06-16 | -8.95 |
| 2025-06-13 | -8.83 |
| 2025-06-12 | -8.95 |
| 2025-06-11 | -8.75 |
| 2025-06-10 | -8.88 |
| 2025-06-09 | -8.78 |
| 2025-06-06 | -8.70 |
| 2025-06-05 | -8.50 |
| 2025-06-04 | -8.53 |
| 2025-06-03 | -8.63 |
| 2025-06-02 | -8.40 |
| 2025-05-30 | -8.40 |
| 2025-05-29 | -8.60 |
| 2025-05-28 | -8.53 |
| 2025-05-27 | -8.63 |
| 2025-05-23 | -8.05 |
| 2025-05-22 | -8.05 |
| 2025-05-21 | -7.93 |
| 2025-05-20 | -8.03 |
| 2025-05-19 | -7.83 |
| 2025-05-16 | -7.70 |
| 2025-05-15 | -7.80 |
| 2025-05-14 | -7.90 |
| 2025-05-13 | -7.98 |
| 2025-05-12 | -8.38 |
| 2025-05-09 | -8.08 |
| 2025-05-08 | -8.25 |
| 2025-05-07 | -8.23 |
| 2025-05-06 | -8.30 |
| 2025-05-05 | -8.78 |
| 2025-05-02 | -8.98 |
| 2025-05-01 | -9.03 |
| 2025-04-30 | -8.88 |
| 2025-04-29 | -8.53 |
| 2025-04-28 | -8.35 |
| 2025-04-25 | -8.23 |
| 2025-04-24 | -8.35 |
| 2025-04-23 | -8.10 |
| 2025-04-22 | -7.98 |
| 2025-04-21 | -8.03 |
| 2025-04-17 | -7.88 |
| 2025-04-16 | -7.65 |